Skip to main content

Analytical Platforms For Supporting Biodistribution Studies For AAV Gene Therapy

 Analytical Consideration For Supporting Biodistribution Studies For AAV Gene Therapy

The biodistribution studies should be designed to answer the following questions

  • Profiling and quantity of the DNA/RNA of the gene therapy products in the different tissues
  • Expression and profiling of the target RNA gene or protein products in different tissues
Profiling and quantity of the DNA/RNA of the gene therapy products in the different tissues

Profiling and quantification of the DNA/RNA of the gene therapy products and biofluids are the primary object of the BD studies. These data provides the selective tropism of the AAV WT, serotypes and AAV variants to the different tissues. It has become even more important as there are increased efforts to identify novel AAVs with improved selective tropism and low immunogenicity. Both screening of natural variants and capsid engineering are extensively employed.  

Currently, real-time quantitative polymerase chain reaction (qPCR) is considered the ‘gold standard’ for measurement of specific DNA (or, with a reverse transcription step, RNA as well) presence in tissues/biofluids. Digital droplet PCR is an emerging platform for these measurement. Quantification of nucleic acid sequences is important for assessing the relative amount of genetic material from a GT product and determining the kinetics of its accumulation or decay. The quantitative methods should be sufficiently sensitive with acceptable reproducibility. 

Expression and profiling of the target RNA gene or protein products in different tissues

In addition of tissue specific tropism of AAV vectors, the tissue specific promoters are engineered to drive the selective expression of the target tissues. For example, albumin promoter or ApoE promoter are used to drive expression in the liver. In these cases, quantitation of the target RNA and proteins provide addition information of the selective expression. It helps identify differential expression of genes in intended vs unintended tissues and evaluate the safety risk and benefit. This also help tease out the correlation of presence of DNA/RNA of gene therapy with the gene expression.

The methods for detection/quantitation of  RNA/proteins include: enzyme-linked immunosorbent assay (ELISA); immunohistochemistry (IHC); western blot; in situ hybridisation (ISH); digital PCR; flow cytometry; various in vivo and ex vivo imaging techniques; and other evolving technologies. 


The details on quantitation methods and case studies are provided in the link below

  • Real Time PCR
  • Digital Droplet PCR
  • Enzyme Linked Immunosorbent Assay 
  • Western Blot 
  • In-Situ Hybridization
  • Flow Cytometry  


Labels:

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more